Research - Concert Pharma (CNCE) is developing a deuterated d-serine as an add-on therapy to existing schizophrenia treatments. In historical academic papers, d-serine has shown to enhance the NMDA … Continue Reading
Premium: Read NowResearch - Yesterday, Affimed (AFMD) announced dosing of the first patient in the Phase 1 trial partnered with MD Anderson. This is the first clinical study combining NK cells … Continue Reading
Premium: Read NowResearch - Iovance (IOVA) traded down 20% in the after hours yesterday after announcing that the FDA required additional potency assays as part of the company’s planned … Continue Reading
Premium: Read NowResearch - Aerpio (ARPO) is starting to see increased interest as trading volume has picked up. Remember that ARPO expects to have Phase 2 top line data … Continue Reading
Premium: Read NowResearch - The $45M financing last August has given Essa enough funding (~$80M cash) to now pursue combination trials with standard of care anti-androgen drugs used in … Continue Reading
Read NowResearch - Trillium (TRIL), a name many readers have expressed interest in, announced two material pieces of news yesterday afternoon. Results from latest Cohort for TTI-622 monotherapy … Continue Reading
Premium: Read NowInsights - Aerpio (ARPO) is developing a novel treatment for glaucoma that has Phase 2 data by the end of 2020. The company’s drug, razuprotafib, has shown to … Continue Reading
Premium: Read Now
